Market report: Investors are trying to stabilize the DAX

Market report DAX closes in the black Clear profits at the start of the week As of: October 26, 2026 • 6:05 p.m

Thanks to a robust ifo business climate, the DAX was able to recover significantly at the start of the week. But this is not yet a trend reversal. There are still some important data coming up this week.

There were signs of recovery on the German stock market today. On the one hand, oil prices came back somewhat from their five-month high at the start of the week. Brent North Sea oil cost just under $112 per barrel in the early evening.

On the other hand, the current ifo business climate index signaled that the economy is continuing to recover. The widely followed leading indicator rose for the sixth month in a row to 90.2 points, the highest level since May 2023.

The mood in the executive suites is brightening: the ifo business climate rose for the sixth time in a row. more

Investors appreciated this and caused the DAX to rise by 0.9 percent to 25,410 points.

Last Friday, the leading German index ended trading at 25,181 points. On a weekly basis it had lost 1.7 percent.

“The first bargain hunters are venturing onto the trading floor and using the cheaper prices to get started,” commented portfolio manager Thomas Altmann from asset manager QC Partners.

Whether this is just a technical reaction to previous losses or a trend reversal remains unclear. “The last few weeks have shown that these bargain hunters realize their profits very quickly in a rising market and thus slow down further price gains,” said Altmann. From a chart perspective, he sees the DAX as “still trapped in its sideways market”.

Nothing has changed in the overall situation and the list of worries and problems is long. The price of oil remains high despite falling prices. Many investors fear that US President Donald Trump will attack Iran again after the US midterm elections.

The question of how long the AI ​​boom will last is also unclear. In the new week, investors are waiting for the balance sheets of the tech giants Alphabet, Microsoft (on Wednesday) and Amazon (on Thursday). If the numbers are strong, that should be reassuring for the time being. But the high expectations can easily be disappointed - with turbulent consequences for the stock markets.

For the time being, however, there were also signs of recovery on the US stock exchanges. Both standard stocks and technology stocks initially gained over half a percent. Because the US has not yet switched to standard time, stock market trading in Central European Time will take place one hour earlier than usual this week.

Economy update from October 26th, 2026 Samir Ibrahim, HR, Economy update, Tagesschau24, October 26th, 2026 • 9:00 a.m. DAX companies also present balance sheets The so far inconsistent reporting season shows that many companies are struggling with the difficult economic conditions, said market analyst Andreas Lipkow from broker CMC Markets. The stock markets now need more than just good news, namely tangible evidence of sustainable growth.

During the week, the chemical company BASF, Deutsche Bank and the car manufacturers Mercedes-Benz and Volkswagen, among others, will present quarterly figures from the DAX.

In addition to the accounting season, monetary policy will be an important topic this week. The US Federal Reserve (Fed) will make its interest rate decision on Wednesday and the European Central Bank (ECB) on Thursday.

“The Fed meets just six days before the US midterm elections,” said chief strategist Robert Greil from private bank Merck Finck. "The continued rise in US inflation actually clearly speaks in favor of an increase in the key interest rate, but the Fed is likely to hold back shortly before the elections, as it has usually done historically." Greil also does not expect any interest rate changes from the ECB on Thursday. However, a further increase is likely for both central banks in December.

Bayer stood out among the individual stocks in the DAX with profits. Traders pointed out that a clinical study had confirmed the effectiveness of the prostate cancer drug Nubeqa. The anticoagulant Asundexian has also been approved in China to prevent secondary strokes.

This topic in the program: tagesschau.de | Stock market 5:45 p.m.: Daily conclusion with closing DAX | 10/26/26 | 5:57 p.m